Results: For all 3 doses of AZD3199, FEV1 E0-4 and E24-26 were statistically significantly greater vs. placebo after 4 weeks' treatment (E0-4 106–171 mL, E24-26 96.5–110 mL) but no dose response was seen (Figure). Formoterol bid was superior to placebo for FEV1 E0-4 but not E24-26. All 3 AZD3199 groups used less reliever medication than the placebo group. AZD3199 did not impact on the acute bronchodilating effect of salbutamol. All AZD3199 groups showed a reduction in symptom scores with the 800 μg dose reaching significance vs. formoterol and placebo. AZD3199 was well tolerated with no safety concerns.